de Sá Dantas Bezerra B, et al. - Authors compared 300 U vs 500 U of abobotulinumtoxinA (ABO) intravesical injections for the treatment of idiopathic overactive bladder (OAB) refractory to first and second-line treatments. They conducted a prospective, randomized, single blind study in female patients with symptoms of OAB, who had failed conservative treatment. Findings suggested an improvement in the symptoms and quality of life for longer period of time with intravesical ABO injection at 500 U than 300 U for idiopathic OAB.